Innovent provides interpretation and updates on clinical data from mazdutide glory-1 study and general biomedicine pipeline

San francisco and suzhou, china , june 27, 2024 /prnewswire/ -- innovent biologics, inc. (innovent) (hkex: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, provided interpretation and updates on clinical data from mazdutide's glory-1 study and its general biomedicine pipeline at an investor conference call on june 25. at the 2024 american diabetes association (ada) scientific meeting, the company reported the results of its first phase 3 clinical study (glory-1) on the glp-1r/gcgr dual agonist mazdutide (innovent r&d code: ibi362) in overweight or obese adults in china, along with the exploratory analysis results on liver fat content.
GM Ratings Summary
GM Quant Ranking